Related Experiment Videos
[Gastrointestinal damage in osteoarthritis patients]
R Fuller1, E Hirose-Pastor, M Levy
1Serviço de Reumatologia, Faculdade de Medicina, Universidade de São Paulo.
Revista Do Hospital Das Clinicas
|March 1, 1997
Summary
Many osteoarthritis patients have gastrointestinal damage before starting nonsteroidal anti-inflammatory drugs (NSAIDs). Endoscopic screening is crucial for identifying risks and guiding protective treatments for NSAID therapy.
Area of Science:
- Gastroenterology
- Rheumatology
- Pharmacology
Context:
- Osteoarthritis (OA) of the hip and knee is a common condition often managed with nonsteroidal anti-inflammatory drugs (NSAIDs).
- Patients indicated for NSAIDs may already have pre-existing gastrointestinal (GI) conditions.
- Anamnesis alone is insufficient for detecting GI damage in these patients.
Purpose:
- To evaluate the prevalence of gastroduodenal damage in symptomatic osteoarthritis patients before initiating NSAID therapy.
- To determine the diagnostic utility of anamnesis versus gastroduodenoscopy for identifying GI lesions.
Summary:
- Seventy-seven OA patients underwent gastroduodenoscopy prior to NSAID treatment.
- Over 54% exhibited gastroduodenal damage, including hyperemia, petechiae, erosions, and peptic ulcers.
- Anamnesis failed to identify these pre-existing conditions.
Impact:
- Endoscopic examination is essential for identifying and excluding gastrointestinal damage before NSAID prescription.
- NSAID therapy requires careful management, including dietetic guidance and gastroprotective agents.
- This highlights the need for proactive GI monitoring in OA patients commencing NSAIDs.